Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.
19 September 2022 - 10:50PM
Business Wire
- Webinar to be hosted on Thursday Sept. 22, 2022 at 12:00 p.m.
ET, register here.
- Dr. Houghton will discuss challenges in drug development for
pediatric cancers and preliminary results from Lantern’s drug
candidates in preclinical pediatric cancer models with unmet
clinical needs.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence ("A.I.") and machine learning (“M.L.”) platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced that it will host a virtual key
opinion leader (KOL) webinar on Sept. 22, 2022 at 12:00 p.m. ET.
The webinar will focus on challenges in drug development for
pediatric cancers and the potential of Lantern’s drug candidates
LP-184 and LP-284 for several rare pediatric cancers.
The webcast will feature a leading expert in pediatric cancer
research, Peter Houghton, Ph.D., Professor & Principal
Investigator at Greehey Children's Cancer Research Institute
(Greehey CCRI) at UT Health Science Center-San Antonio. During the
webcast, Dr. Houghton will discuss the disparities and hurdles that
currently exist in pediatric cancer research, drug development, and
clinical trial design compared to adults. He will also provide
details on exciting new preclinical results for LP-284 and its
preclinical efficacy in vivo for several pediatric cancer models
including Ewing’s sarcoma, malignant rhabdoid tumors, and alveolar
rhabdomyosarcomas. Details on the webinar and how to register can
be found below:
Virtual KOL Webinar Details:
- When: Thursday, September 22, 2022 at 12:00 p.m. ET
- Webinar Length: 20 minutes
- Registration, please use the link below:
https://us06web.zoom.us/webinar/register/7916625619023/WN_RmePEGlpSviaLTsECKdaVA
- A replay of the webinar will be available on Lantern’s website
beginning on September 23, 2022: www.lanternpharma.com
In early 2022, Lantern entered a research collaboration with Dr.
Houghton to evaluate Lantern’s drug candidates LP-184 and LP-284 in
several pediatric cancer models. Preliminary results from the
initial phase of the LP-284 experiments have been obtained, with
additional experiments planned for both LP-184 and LP-284 in the
second half of 2022.
About Dr. Peter Houghton:
Dr. Houghton is an internationally recognized researcher in
pediatric oncology and drug development. He received his Ph.D. in
1976 from the Institute of Cancer Research at the University of
London, after which he spent over 30 years with St. Jude Children’s
Research Hospital where he was the chair of Molecular Pharmacology
and co-leader of the Solid Malignancies Research Program. Most
recently, he served as the Director of the Greehey CCRI at UT
Health Science Center-San Antonio from 2014 to 2021. At the Greehey
CCRI, Dr. Houghton’s laboratory focuses on the development of novel
approaches for the treatment of pediatric cancers, which has
included creating of one of the most comprehensive patient-derived
xenograft (PDX) model libraries for pediatric cancers. These PDX
models are a critical resource to evaluate novel therapeutics in
clinically relevant pediatric cancer models.
About the Greehey CCRI:
Since 2004, UT Health San Antonio, Greehey CCRI’s mission has
been to advance scientific knowledge relevant to childhood cancer,
contribute to understanding its causes, and accelerate the
translation of knowledge into novel therapies. Greehey CCRI strives
to have a national and global impact on childhood cancer by
discovering, developing, and disseminating new scientific
knowledge. More information on the Greehey CCRI can be found on
their Website, Facebook, Twitter, LinkedIn, and Instagram.
About Lantern Pharma:
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage
oncology-focused biopharmaceutical company leveraging its
proprietary RADR® A.I. and machine learning platform to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically targeted therapeutics. Lantern is
currently developing four drug candidates and an ADC program across
nine disclosed tumor targets, including two phase 2 programs. By
targeting drugs to patients whose genomic profile identifies them
as having the highest probability of benefiting from the drug,
Lantern's approach represents the potential to deliver
best-in-class outcomes.
Please find more information at:
Website: www.lanternpharma.com LinkedIn:
https://www.linkedin.com/company/lanternpharma/ Twitter:
@lanternpharma
Lantern’s Investor Relations Contact:
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; expectations and estimates regarding clinical trial timing
and patient enrollment; our research and development efforts of our
internal drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug candidates and
our plans to discover and develop drug candidates and to maximize
their commercial potential by advancing such drug candidates
ourselves or in collaboration with others. Any statements that are
not statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "objective," "aim," "upcoming," "should," "will,"
"would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® A.I. platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the Securities and Exchange Commission on March 10,
2022. You may access our Annual Report on Form 10-K for the year
ended December 31, 2021 under the investor SEC filings tab of our
website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220919005207/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024